Ironwood Pharmaceuticals Inc. shares surged 3.5% in premarket trade Monday, after the company reported positive results in mid-stage trials of a treatment for diabetes with hypertension. The company said data from two Phase IIa trial of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator, in patients with type 2 diabetes and hypertension produced positive results, including blood pressure reductions and improvements in fasting plasma glucose and cholestrol levels. “These data further reinforce our commitment to developing IW-1973 in patients with diabetic nephropathy and in patients with HFpEF, two diseases of significant unmet need estimated to affect millions of patients around the world, and we are advancing our ongoing larger Phase II trials in these indications,” Christopher Wright, MD, PhD, senior vice president of global development and chief development officer at Ironwood, said in a statement. Shares have gained 13% in 2017, while the S&P 500 has gained 18%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News